New and emerging antifungal agents: impact on respiratory infections.
Fungal pathogens are increasingly important causes of respiratory disease, yet the number of antifungal agents available for clinical use is limited. Use of amphotericin B deoxycholate is hampered by severe toxicity. Triazole agents currently available have significant drug interactions; fluconazole has a limited spectrum of activity and itraconazole was, until recently, available only in oral formulations with limited bioavailability. The development of resistance to all three agents is increasingly being recognized and some filamentous fungi are resistant to the action of all of these agents. In the past few years, new antifungal agents and new formulations of existing agents have become available.The use of liposomal amphotericin B preparations is associated with reduced, but still substantial, rates of nephrotoxicity and infusion-related reactions. An intravenous formulation of itraconazole has been introduced, and several new triazole agents have been developed, with the view of identifying agents that have enhanced potency, broader spectra of action and improved pharmacodynamic properties. One of these, voriconazole, has completed large-scale clinical trials. In addition, caspofungin, the first of a new class of agents, the echinocandins, which inhibit cell wall glucan synthesis, was approved for use in the US in 2001 as salvage therapy for invasive aspergillosis. It is hoped that the availability of these agents will have a significant impact on the morbidity and mortality of fungal respiratory infections. However, at the present time, our ability to assess their impact is limited by the problematic nature of conducting trials for antifungal therapy.
Feldmesser
Marta
M
Departments of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, USA. feldmess@aecom.yu.edu
D000935:Antifungal Agents / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D000935:Antifungal Agents